• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Integration Of Targeted Therapies With Radiation Lung Cancer
 

Integration Of Targeted Therapies With Radiation Lung Cancer

on

  • 2,866 views

 

Statistics

Views

Total Views
2,866
Views on SlideShare
2,862
Embed Views
4

Actions

Likes
1
Downloads
126
Comments
0

2 Embeds 4

http://radiotherapyhome-fondas.blogspot.com 2
http://www.slideshare.net 2

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Integration Of Targeted Therapies With Radiation Lung Cancer Integration Of Targeted Therapies With Radiation Lung Cancer Presentation Transcript

    • Integration of targeted therapies with radiation Lung Cancer Robert Pirker Medical University of Vienna ESMO/ESTRO/ESSO Joint Symposium 33rd ESMO Congress, Stockholm 2008
    • NSCLC III Therapy • Stage III is heterogeneous • Prognosis dependent on lymph node involvement: N2 versus N3 minimal, clinical, „bulky“ • Local therapy and systemic chemotherapy • Optimal therapy for various subgroups unclear
    • NSCLC stage III Therapeutic options CT RT CT-RT Induction CT CT-RT CT-RT Consolidation CT Inclusion of surgery (trimodality therapy) New radiotherapy techniques PCI Targeted therapy
    • Integration of targeted therapies into the therapy of NSCLC stage III • Adjuvant therapy after complete tumor resection – Combined with adjuvant chemotherapy • Initial therapy in unresectable disease – Combined with chemoradiotherapy – Combined with radiotherapy – Combined with chemotherapy • Maintenance therapy • Monotherapy or in combination
    • Targeted Therapies in advanced NSCLC • EGFR-directed therapies • Angiogenesis inhibitors • Dual & multikinase inhibitors • Others
    • EGF-R as a target • EGFR expression in 40-80% of NSCLC • EGFR expression is associated with tumor proliferation, invasiveness, angiogenesis & shorter survival times • EGFR expression associated with radioresistance & preclinical models suggest radiosensitization following inhibition of EGFR signaling • Efficacy shown for – TKIs in pre-treated patients with advanced NSCLC – Cetuximab + chemotherapy in advanced NSCLC – Cetuximab + radiotherapy in head & neck cancer Bonner JA et al. NEJM 2006, 354, 567
    • EGFR Inhibitors • Monoclonal antibodies – Cetuximab (ERBITUX®) – Matuzumab – Panitumumab • Tyrosine kinase inhibitors – Gefitinib – Erlotinib – Vandetanib (ZD6474; EGFR, VEGFR) – Lapatinib (GW572016; EGFR, ErbB2) – others
    • NSCLC III Chemoradiotherapy (or RT) + Cetuximab • SCRATCH Hughes SR et al. ASCO 2007, abstract 18032 Radiotherapy + cetuximab: phase I trial • RTOG 0324 phase II trial Blumenschein GR et al. ASCO 2008, abstract 7516 Carboplatin/paclitaxel + radiotherapy + cetuximab • CAGLB 30407 randomized phase II trial Govindan R et al. ASCO 2008, abstract 7518 Carboplatin/pemetrexed + radiotherapy +/- cetuximab
    • NSCLC III CRT + Cetuximab: RTOG 0324 phase II trial Blumenschein GR et al. ASCO 2008, abstract 7516 • Carboplatin AUC 2 weekly + paclitaxel 45 mg/m2 weekly (6x) plus cetuximab plus 63 Gy; Carboplatin AUC 6 + paclitaxel 200 mg/m2 + cetuximab (2x) • 93 (87) patients: 57% male, median 64 years, 47% PS 0, 46% IIIA • RR 62%, median OS 23 months, 2-yr OS 49% • Grade ¾ toxicity: hematotoxicity 20% esophagitis 8% pneumonitis 7% 5 treatment-related deaths
    • NSCLC III Chemoradiotherapy + Cetuximab Blumenschein GR et al. ASCO 2008, abstract 7516 • Feasible and safe • Active with OS better than previously reported • Phase III trial
    • NSCLC III Chemoradiotherapy + Cetuximab Olsen CC et al. ASCO 2008, abstract 7607 • RTOG 0324 phase II trial • 93 (87) patients • FISH analysis in 45 patients FISH + FISH - 2-year OS 62% 54% CR/PR 24% 8% • Conclusion: Tissue testing is feasible FISH-positive patients might have a better response
    • NSCLC III CRT + Cetuximab: CALGB 30407 trial Govindan R et al. ASCO 2008, abstract 7518 • Carboplatin AUC 5 + pemetrexed 500 mg/m2, 4x with/without cetuximab (400, then weekly 250 mg/m2) plus 70 Gy; Carboplatin AUC 5 + pemetrexed 500 mg/m2, 4x • 106 patients: 61% male, median 64.5 years, 39% adeno Cetuximab Control Neutropenia 3/4 37% 36% Esophagitis 3/4 22% 35% Skin rash 23% 3%
    • NSCLC III Chemoradiotherapy + Cetuximab • Based on – the results of these phase II trials, – the efficacy of cetuximab in combination with chemotherapy in advanced NSCLC, and – the positive results in head & neck cancer, a phase III trial is warranted: Inoperable stage III NSCLC Cisplatin-based doublet (e.g. cis/etoposide, cis/vinorelbine) + radiotherapy ± cetuximab Primary endpoint: overall survival
    • NSCLC III EGFR-directed tyrosine kinase inhibitors • Chemoradiotherapy + TKIs – Gefitinib Rischin D et al. ASCO 2004, abstract 7077 Ready N et al. ASCO 2006, abstract 7046 – Erlotinib Hoffmann PC et al. ASCO 2005, abstract 7113 • TKI maintenance – Gefitinib Kelly K et al. ASCO 2007, abstract 7513 – Erlotinib Casal J et al. ASCO 2008, abstract 18501
    • NSCLC III Chemoradiotherapy + Gefitinib CALGB 30106 Ready N et al. ASCO 2006, abstract 7046 Carbo AUC 6 + paclitaxel 200 mg/m2 + gefitinib 250 mg (2x) PS 0/1 PS 2 or poor risk carbo AUC 2 wkly gefitinib paclitaxel 50 mg/m2 wkly RT gefitinib RT OS 9 months 19 months
    • NSCLC III Gefitinib maintenance • Survival disadvantage after chemoradiotherapy (SWOG 0023) Kelly K et al. ASCO 2007, abstract 7513 Concurrent chemoradiotherapy (575 pts.) Docetaxel consolidation Randomization (263 pts.): Gefitinib 250 mg or Placebo Gefitinib Placebo n 118 125 OS mo 23 35 p=0.01 Disease progression as primary cause of death
    • NSCLC III Chemoradiotherapy + tyrosine kinase inhibitors • Combination of chemoradiotherapy with TKIs is feasible • Maintenance with gefitinib failed • TKIs did not improve outcome of chemotherapy in advanced NSCLC • Further trials ?
    • NSCLC III Angiogenesis inhibitors • Increase antitumor activity of both cytotoxic drugs and radiotherapy • Several angiogenesis inhibitors – Bevacizumab – Thalidomide – Vandetanib (ZD6474) – others
    • NSCLC III Chemoradiotherapy + Bevacizumab Socinski MA et al. ASCO 2008, abstract 7517 • Carboplatin AUC 6 + paclitaxel 225 mg/m2 + bevacizumab (15 mg/kg), 2x • Carboplatin AUC 2 weekly + paclitaxel 45 mg/m2 weekly (7x) plus 74 Gy (2 Gy per fraction) Cohorts Bevacizumab Erlotinib I 10 0 II 10 100 III 10 150
    • NSCLC III Chemoradiotherapy + Bevacizumab Socinski MA et al. ASCO 2008, abstract 7517 • Conclusions – Incorporation of bevacizumab & erlotinib is feasible – Esophagitis more common than previous experience – Phase II continuing • However, limitations due to – Carboplatin-based protocol – Complex trial design (2 targeted therapies) – Interpretation will be difficult
    • SCLC Bevacizumab • Irinotecan/carboplatin/bevacizumab in SCLC ED (phase II) Spigel DR et al. JCO 25, 18S, 2007 36 patients, 78% PR, no bleedings gr 3/4 • Tracheo-esophageal fistula Spigel DR et al. ASCO 2008, 7554 29 patients with irinotecan/carboplatin plus bevacizumab plus concurrent radiotherapy 2 events (1 fatal), another fatal event with suspected fistula
    • Lung Cancer Chemoradiotherapy + angiogenesis inhibitors • Carboplatin-based protocols • Insufficient data • Tacheoesophageal fistula, other toxicities?
    • BLP25 Liposome Vaccine in NSCLC Butts CA et al. JCO 23, 6674, 2005 • Randomized, open-label phase II • 171 pts. responding to 1st line chemotherapy: 65 pts with IIIB, 106 pts. with wet IIIB or IV • L-BLP25 (BLP25 Liposome Vaccine): 8 weekly subcutaneous vaccinations: • OS: all pts. 17.4 vs 13 months, p=0.11 IIIB pts. Not yet reached vs 13 months, p=0.07 2-year survival 60% versus 37% • Phase III trial ongoing (START)
    • NSCLC III Targeted therapy plus chemoradiotherapy Summary • New treatment options • Integration is complex • Results from phase II trials with cetuximab warrant a phase III trial chemoradiotherapy ± cetuximab • Further studies on EGFR-directed tyrosine kinase inhibitors ? • Insufficient data on angiogenesis inhibitors but toxicity might become an issue • Phase III vaccination trial ongoing (START) • Simple but relevant trials required